Legal Representation
Attorney
Leesa N. Weiss
USPTO Deadlines
Next Deadline
7 days remaining
Statement of Use Due - Extension 1 Granted
Due Date
August 06, 2025
Extension Available
Until August 06, 2025
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Feb 7, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 6, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 6, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Feb 6, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 6, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 11, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 11, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 22, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 8, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 6, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 6, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 6, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 7, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 7, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 7, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 25, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 27, 2023 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| May 26, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 2, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
vaccines for infectious disease, cancer, heart disease, and rare diseases; therapeutic preparations for the treatment of cancer, heart disease and rare hereditary and infectious diseases
Class 044
immunotherapy, stem cell therapy, and chemotherapy for the treatment cancer, heart disease and rare hereditary and infectious diseases
Additional Information
Design Mark
The mark consists of the wording "RNAIMMUNE" inside a stylized representation of a partial double helix.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
RNA IMMUNE
Classification
International Classes
005
044